Skip Nav Destination
Issues
15 December 2022
-
Cover Image
Cover Image
The cover shows a section of a human lung adenocarcinoma from a mouse xenograft model. Immunofluorescence staining shows a robust expression of FAP as a result of the recruitment and invasion of host (mouse) fibroblasts to the tumor stroma. For details, see the article by Lee and colleagues on page 5330 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease
M. Naomi Horiba; Sandra J. Casak; Pallavi S. Mishra-Kalyani; Pourab Roy; Julia A. Beaver; Richard Pazdur; Paul G. Kluetz; Steven J. Lemery; Lola A. Fashoyin-Aje
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer
Mirat Shah; Christy L. Osgood; Anup K. Amatya; Mallorie H. Fiero; William F. Pierce; Abhilasha Nair; Jonathan Herz; Kim J. Robertson; Bronwyn D. Mixter; Shenghui Tang; Richard Pazdur; Julia A. Beaver; Laleh Amiri-Kordestani
Research Briefs: Clinical Trial Brief Reports
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner; Katrina Pedersen; Benjamin Tan; Nicholas Boice; Abhi Acharya; Mina Abdiannia; Feng Gao; Harry H. Yoon; Mojun Zhu; Nikolaos A. Trikalinos; Lee Ratner; Olivia Aranha; William G. Hawkins; Brett H. Herzog; David G. DeNardo
Clinical Trials: Targeted Therapy
A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer
Kathy Han; Anthony Fyles; Tina Shek; Jennifer Croke; Neesha Dhani; David D'Souza; Ting-Yim Lee; Naz Chaudary; Jeffrey Bruce; Melania Pintilie; Rob Cairns; Douglass Vines; Sara Pakbaz; David Jaffray; Ur Metser; Marjan Rouzbahman; Michael Milosevic; Marianne Koritzinsky
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Daniel A. Pollyea; Keith W. Pratz; Andrew H. Wei; Vinod Pullarkat; Brian A. Jonas; Christian Recher; Sunil Babu; Andre C. Schuh; Monique Dail; Yan Sun; Jalaja Potluri; Brenda Chyla; Courtney D. DiNardo
Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study
Xin Liu; Shiyu Jiang; Huijie Wang; Xianghua Wu; Wangjun Yan; Yong Chen; Yu Xu; Chunmeng Wang; Weiqiang Yao; Jian Wang; Lin Yu; Jiashun Miao; Hao Chen; Jing Xia; Mengli Huang; Xiaowei Zhang; Zhiguo Luo
Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
Zhi-ming Wang; Rong-yuan Zhuang; Xi Guo; Chen-lu Zhang; Yang You; Li-sha Chen; Wen-shuai Liu; Yong Zhang; Rong-kui Luo; Ying-yong Hou; Wei-qi Lu; Yu-hong Zhou
Clinical Trials: Immunotherapy
SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study
Jifeng Feng; Dihong Tang; Jing Wang; Qi Zhou; Jin Peng; Hanmei Lou; Yuping Sun; Yunlang Cai; Hongmin Chen; Junqin Yang; Pan Liu; Linna Wang; Jianjun Zou
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Casey L. O'Connell; Maria R. Baer; Andreas Due Ørskov; Sunil Kumar Saini; Vu H. Duong; Patricia Kropf; Jakob Werner Hansen; Denice Tsao-Wei; Hyo Sik Jang; Ashkan Emadi; Staffan Holmberg-Thyden; Jack Cowland; Brett T. Brinker; Kristin Horwood; Ryan Burgos; Galen Hostetter; Benjamin A. Youngblood; Sine Reker Hadrup; Jean-Pierre Issa; Peter Jones; Stephen B. Baylin; Imran Siddiqi; Kirsten Grønbaek
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
MacLean S. Hall; John E. Mullinax; Cheryl A. Cox; Amy M. Hall; Matthew S. Beatty; Jamie Blauvelt; Patrick Innamarato; Luz Nagle; Holly Branthoover; Doris Wiener; Benjamin Schachner; Alberto J. Martinez; Allison D. Richards; Carolyn J. Rich; Marjorie Colón Colón; Michael J. Schell; Jamie K. Teer; Nikhil I. Khushalani; Jeffrey S. Weber; James J. Mulé; Vernon K. Sondak; Shari Pilon-Thomas; Amod A. Sarnaik
Precision Medicine and Imaging
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
Iris K. Lee; Estela Noguera-Ortega; Zebin Xiao; Leslie Todd; John Scholler; Decheng Song; Maria Liousia; Katheryn Lohith; Kexiang Xu; Kimberly J. Edwards; Michael D. Farwell; Carl H. June; Steven M. Albelda; Ellen Puré; Mark A. Sellmyer
Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Nicolas A. Giraldo; Esther Drill; Baby A. Satravada; Imane El Dika; A. Rose Brannon; Josephine Dermawan; Abhinita Mohanty; Kerem Ozcan; Debyani Chakravarty; Ryma Benayed; Efsevia Vakiani; Ghassan K. Abou-Alfa; Ritika Kundra; Nikolaus Schultz; Bob T. Li; Michael F. Berger; James J. Harding; Marc Ladanyi; Eileen M. O'Reilly; William Jarnagin; Chad Vanderbilt; Olca Basturk; Maria E. Arcila
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Jian Wang; Tobias Weiss; Marian C. Neidert; Nora C. Toussaint; Reza Naghavian; Carla Sellés Moreno; Magdalena Foege; Paula Tomas Ojer; Gioele Medici; Ivan Jelcic; Daniel Schulz; Elisabeth Rushing; Susanne Dettwiler; Barbara Schrörs; Joo Heon Shin; Ron McKay; Catherine J. Wu; Andreas Lutterotti; Mireia Sospedra; Holger Moch; Erich F. Greiner; Bernd Bodenmiller; Luca Regli; Michael Weller; Patrick Roth; Roland Martin
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Nicola S. Meagher; Kylie L. Gorringe; Matthew Wakefield; Adelyn Bolithon; Chi Nam Ignatius Pang; Derek S. Chiu; Michael S. Anglesio; Kylie-Ann Mallitt; Jennifer A. Doherty; Holly R. Harris; Joellen M. Schildkraut; Andrew Berchuck; Kara L. Cushing-Haugen; Ksenia Chezar; Angela Chou; Adeline Tan; Jennifer Alsop; Ellen Barlow; Matthias W. Beckmann; Jessica Boros; David D.L. Bowtell; for the AOCS Group; Alison H. Brand; James D. Brenton; Ian Campbell; Dane Cheasley; Joshua Cohen; Cezary Cybulski; Esther Elishaev; Ramona Erber; Rhonda Farrell; Anna Fischer; Zhuxuan Fu; Blake Gilks; Anthony J. Gill; for the Australian Pancreatic Genome Initiative; Charlie Gourley; Marcel Grube; Paul R. Harnett; Arndt Hartmann; Anusha Hettiaratchi; Claus K. Høgdall; Tomasz Huzarski; Anna Jakubowska; Mercedes Jimenez-Linan; Catherine J. Kennedy; Byoung-Gie Kim; Jae-Weon Kim; Jae-Hoon Kim; Kayla Klett; Jennifer M. Koziak; Tiffany Lai; Angela Laslavic; Jenny Lester; Yee Leung; Na Li; Winston Liauw; Belle W.X. Lim; Anna Linder; Jan Lubiński; Sakshi Mahale; Constantina Mateoiu; Simone McInerny; Janusz Menkiszak; Parham Minoo; Suzana Mittelstadt; David Morris; Sandra Orsulic; Sang-Yoon Park; Celeste Leigh Pearce; John V. Pearson; Malcolm C. Pike; Carmel M. Quinn; Ganendra Raj Mohan; Jianyu Rao; Marjorie J. Riggan; Matthias Ruebner; Stuart Salfinger; Clare L. Scott; Mitul Shah; Helen Steed; Colin J.R. Stewart; Deepak Subramanian; Soseul Sung; Katrina Tang; Paul Timpson; Robyn L. Ward; Rebekka Wiedenhoefer; Heather Thorne; for the kConFab Investigators; Paul A. Cohen; Philip Crowe; Peter A. Fasching; Jacek Gronwald; Nicholas J. Hawkins; Estrid Høgdall; David G. Huntsman; Paul A. James; Beth Y. Karlan; Linda E. Kelemen; Stefan Kommoss; Gottfried E. Konecny; Francesmary Modugno; Sue K. Park; Annette Staebler; Karin Sundfeldt; Anna H. Wu; Aline Talhouk; Paul D.P. Pharoah; Lyndal Anderson; Anna DeFazio; Martin Köbel; Michael L. Friedlander; Susan J. Ramus
Translational Cancer Mechanisms and Therapy
HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Yuanqing Ma; Allison Joyce; Olivia Brandenburg; Faeze Saatchi; Christina Stevens; Vanina Toffessi Tcheuyap; Alana Christie; Quyen N. Do; Oluwatomilade Fatunde; Alyssa Macchiaroli; So C. Wong; Layton Woolford; Qurratulain Yousuf; Jeffrey Miyata; Deyssy Carrillo; Oreoluwa Onabolu; Tiffani McKenzie; Akhilesh Mishra; Tanner Hardy; Wei He; Daniel Li; Alexander Ivanishev; Qing Zhang; Ivan Pedrosa; Payal Kapur; Thomas Schluep; Steven B. Kanner; James Hamilton; James Brugarolas
Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Kyung-Don Kang; Joshua D. Bernstock; Stacie K. Totsch; Sam E. Gary; Abbey Rocco; Li Nan; Rong Li; Tina Etminan; Xiaosi Han; Elizabeth A. Beierle; Tanja Eisemann; Robert J. Wechsler-Reya; Sejong Bae; Richard Whitley; G. Yancey Gillespie; James M. Markert; Gregory K. Friedman
FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
Vishwajith Sridharan; Azfar Neyaz; Abhijit Chogule; Islam Baiev; Stephanie Reyes; Emily G. Barr Fritcher; Jochen K. Lennerz; William Sukov; Benjamin Kipp; David T. Ting; Vikram Deshpande; Lipika Goyal
Fibroblast Activation Protein Triggers Release of Drug Payload from Non-internalizing Small Molecule Drug Conjugates in Solid Tumors
Aureliano Zana; Andrea Galbiati; Ettore Gilardoni; Matilde Bocci; Jacopo Millul; Theo Sturm; Riccardo Stucchi; Abdullah Elsayed; Lisa Nadal; Martina Cirillo; Wolfgang Roll; Lars Stegger; Inga Asmus; Philipp Backhaus; Michael Schäfers; Dario Neri; Samuele Cazzamalli
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Jing Deng; Aneel Paulus; Douglas D. Fang; Alak Manna; Guangfeng Wang; Hengbang Wang; Saijie Zhu; Jianyong Chen; Ping Min; Yan Yin; Navnita Dutta; Nabanita Halder; Gina Ciccio; John A. Copland, III; James Miller; Bing Han; Longchuan Bai; Liu Liu; Mi Wang; Donna McEachern; Sally Przybranowski; Chao-Yie Yang; Jeanne A. Stuckey; Depei Wu; Caixia Li; Jeremy Ryan; Anthony Letai; Sikander Ailawadhi; Dajun Yang; Shaomeng Wang; Asher Chanan-Khan; Yifan Zhai
Correction
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
John F.R. Robertson; Robert E. Coleman; Kwok-Leung Cheung; Abigail Evans; Chris Holcombe; Anthony Skene; Daniel Rea; Samreen Ahmed; Ali Jahan; Kieran Horgan; Petra Rauchhaus; Roberta Littleford; S.Y. Amy Cheung; Marie Cullberg; Elza C. de Bruin; Loumpiana Koulai; Justin P.O. Lindemann; Martin Pass; Paul Rugman; Gaia Schiavon; Rahul Deb; Pauline Finlay; Andrew Foxley; Julia M.W. Gee
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds